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Time depended Bcl-2 inhibition might 
be useful for a targeted drug therapy
Abdolhassan Talaiezadeh1, Fateme jalali2, Hamid Galehdari2* and Ali Khodadadi1,3
Background: Over expression of Bcl-2 is frequently observed in several types of cancers and it is one of the prognos-
tic markers in breast cancer. The importance of the Bcl-2 protein as ideal therapeutic target is the dual role of inhibit-
ing apoptosis and autophagy-mediated cell death. Thus, the bcl-2 targeting may be a strategy of choice to improve 
treatment efficacy and overcome drug resistance to cancer chemotherapy. For this reason, we designed the siRNA 
mediated silencing of the Bcl-2 gene in the MCF-7 breast cancer cell line.
Objectives: The purpose of this research was to investigate the effective Bcl-2 gene silencing by our homemade 
siRNA, more than previous study. Our data demonstrated that specific inhibition of the Bcl-2 by siRNA induces 
approximately more than 90 % gene silencing.
Methods: MCF-7 Cell lines were treated by homemade Bcl-2siRNA for the first time and control siRNA that was 
transfected with nanoparticle. The cells harvested at 24, 48 and 72 h and transcription level of Bcl-2 was examined 
by Real Time -PCR analysis. The drug sensitivity was detected by using LDH assay test. Finally Anexin V-FITC test was 
performed for evaluation of apoptosis.
Results: In the present study, results showed that targeting the specific sequence of the Bcl-2 by our homemade 
siRNA in the MCF7 cell line and its effect was more obvious in 24 h in contrast to 48 and 72 h.
Conclusions: However, we showed here a time dependent blocking of the bcl-2 transcript that might lead to cell 
dead due autophagy, and not necessarily to apoptosis.
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Background
When cell is able to overcome a number of failsafe mech-
anisms, including apoptotic and autophagic cell death, 
and is also able to induce oncogene activation and tumor 
suppressor inactivation, it is said that the cell is cancerous 
[1]. Among women, breast cancer is the most frequently 
diagnosed cancer and the leading reason of cancer death, 
reported for 23 % of the total cancer cases and 14 % of the 
cancer deaths [2]. It is the most prevalent cancer both in 
the developed and developing countries.
Its development process involves decreasing expression 
of apoptosis gene and overexpression of anti-apoptosis 
and the genes involving in inhibition of autophagy such 
as BAD and Bcl-2, respectively [3–5].
Treatments include surgery, radiation therapy, chemo-
therapy [6]. While chemotherapy is an important therapy 
to breast cancer, the result of it in breast cancer is not 
ideal [3].
Overexpression of Bcl-2 is frequently observed in sev-
eral types of cancer such as breast, lung, ovarian, mela-
noma cancers, and is often associated with unfavorable 
outcome [7–10]. So impairment of Bcl-2 gene expres-
sion is a hallmark of cancer and can result in resistance to 
chemotherapy [11, 12].
The important reason that creates Bcl-2 protein as an 
ideal therapeutic target is the dual role of it in inhibiting 
both apoptosis and autophagic-associated cell death [13, 
14].
Apoptosis (self-killing) and autophagy (self-eating) 
are two self-destructive processes which have captured 
the attention of researchers over the last decades. While 
apoptosis includes the activation of catabolic enzymes 
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leading to the destruction of cellular structures and 
organelles, autophagy is a slow, localized phenomenon 
which contains the sequestration of cytoplasmic constit-
uents (including organelles and long-lived proteins) into 
double-membrane-bound vesicles or autophagosomes, 
which ultimately fuse with lysosomes for degradation 
[15, 16]. These pathways are two key signaling pathways 
employed by the cell in response to different inducers. 
The mechanisms of them are different, and involve basi-
cally diverse sets of regulatory and executioner molecules 
[17–19].
Bcl-2 suppress apoptosis by binding to Bax or Bak, 
and inhibit autophagy by binding to the protein Beclin 
1, which is required for the initiation of autophagasome 
formation in autophagy [20–22]. Therefore, Bcl-2 not 
only functions as an anti-apoptotic protein, but also as an 
anti-autophagy protein via its inhibitory interaction with 
Beclin 1 [7].
So the crosstalk between apoptosis and autophagy is 
complex in nature, and sometimes inconsistent, but cer-
tainly acute to the overall fate of the cell [23].
It is proposed that functional blockage of the anti-
apoptotic Bcl-2 gene could possibly change the balance 
of the apoptotic and autophagy machinery in tumor cells 
and sensitizes them to chemo and radiotherapy. Thus, 
targeting of Bcl-2 may be a strategy of choice to improve 
treatment efficacy and overcome drug resistance to can-
cer chemotherapy. Small interfering RNA (siRNA) is 
also a powerful tool to validate the targets of therapeu-
tic drugs. RNAi is being explored as a powerful tool to 
inhibit the expression of genes involved in oncogenes and 
genes that are involved in angiogenesis, metastasis, sur-
vival, anti-apoptosis and resistance to chemotherapy [24, 
25]. And it has shown great promise for many diseases 
such as cancer.
The silencing effect of siRNAs isn’t long-lived, since the 
siRNAs ultimately decay within the cell [25], and this can 
be an advantage because this method is used to increase 
the efficiency of chemotherapy which is done in a short 
period of time.
Synthetic siRNAs strongly inhibit expression of the tar-
get gene in mammalian cells when they are transfected 
into the cells by cationic liposomes [26].
Objectives
Resistance to chemotherapeutic agents is a major factor 
confounding cancer treatment. siRNAs have been used to 
decrease the drug resistance of cells in vitro by inhibiting 
the expression of Bcl-2. The degree of siRNA-mediated 
gene silencing was consistent with other reports where 
antisense reagents of several types were used to target 
Bcl-2 [27–30].
The purpose of the study was to investigate the possi-
bility of Bcl-2 gene silencing by our homemade siRNA.
Methods
Cell calture
As Bcl-2 is an effective target for gene silencing in MCF-7 
breast cancer cells, this cell line was obtained from Pas-
teur Institute of Iran. And then was cultured in RPMI-
1640 medium containing 10 % fetal bovine serum (FBS) 
and 1 % penicillin–streptomycin under standard culture 
conditions (37 °C, 95 % humidified air and 5 % CO2).
Transfection of siRNA
First, in six-well tissue culture plates containing 2  mL 
antibiotic-free normal growth medium supplemented 
with FBS, 2 ×  105 cells per well were seeded. The cells 
were then Incubated at 37  °C in a CO2 Incubator until 
they were 60–80 % confluent (This takes 18–24 h). Then 
the siRNA duplex solution was then added directly to the 
dilute Transfection Reagent using a pipette and mixed 
gently by pipetting the solution up and down. The mix-
ture were incubated at room temperature for 15–45 min, 
and washed with 2 mL of siRNA transfection medium.
For each transfection, 0.8  mL of siRNA transfection 
medium was added to each tube containing the siRNA 
transfection reagent mixture, and was mixed gently and 
covertly the mixture on to the washed cells. The cells 
were then incubated in a CO2 incubator at 37  °C for 
5–7 h.
The siRNA sequence which was supposed to targete 
bcl-2 was designed by Genescript, and is shown below: 
Bcl2sense:5′-UCAGUAGGUGUCCCGCUACTT-3′ 
bcl-2 antisense: 5′-TTAGUCAUCCAC AGGGCGAU 
G-3′. To determine that our homemade siRNA is the 
effector molecules of the RNAi pathway, we used control 
(no targeting) siRNA duplexes which have four or more 
mismatches with all known human mRNAs, and have no 
homology with any known gene (Fig.  1). The cells were 
transfected with siRNA according to the manufacturer’s 
instructions. On the day of transfection, the medium was 
replaced by 2 mL of fresh medium and 1 μg of siRNA, and 
then was mixed with the transfection reagent. All experi-
ments were performed at 24, 48 and 72 h post transfec-
tion. Finally cells were harvested for analysis 72  h after 
transfection. For enhancing the transfection efficiency, 
the cells were transfected with the non-silencing FITC-
labeled siRNA for 4  h, washed with phosphate-buffered 
saline twice, and counted in a fluorescent microscope 
(Figs. 1 and 2). After treatments, the cells were harvested 
at different time including 24, 48 and 72 h for real-time 
analysis and for evaluation of apoptosis and autophagy 
state as well.
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Total RNA extraction and cDNA synthesis
Total cellular RNA was isolated using the RNeasy Mini 
Kit (Qiagen, Valencia, CA). According to manufacturer’s 
instructions and then was quantified by nanodrop.
cDNA synthesis was performed using BIONER cDNA 
Synthesis Kit. And then cDNA was verified by PCR using 
gene specific primers for GAPDH as an internal control.
Real‑timePCR
The sequences of Real-Time reverse transcription-pol-
ymerase chain reaction amplification of Bcl-2, GAPDH 
cDNA, and Bcl-2 primers were (5′-GGAGAGTGCTGAA 
GATTGATG-3′), (5′-AGTCTACTTCCTCTGTGATGT 
TG-3′), for forward and reverse respectively.
GAPDH primers were (5´-AGGGCTGCTTTTAACT 
CTGGT-3´), (5´-CCCCACTTGATTTTGGAGGGA -3′) 
for forward and reverse respectively.
Analysis of apoptosis
To provide a comparative assay of apoptosis by Annexin 
V labeling, tumor cells (1 × 106) were treated with Bcl-2 
siRNA for 24–72 h and then were harvested and washed 
with PBS. Cells were resuspended in binding buffer 
and stained with Annexin V and propidium iodide (PI) 
according to manufacturer’s protocol (Abcam Kit), con-
trol and treated cells were detected and quantified by 
FACS analysis.
Lactate dehydrogenase activity‑based cytotoxicity Assays
Non-radioactive colorimetric assay is suitable for high-
throughput quantification of cell death and cell lysis, 
based on measurement of lactate dehydrogenase (LDH) 
activity released from the cytosol of damaged cells. To do 
this, we let the cells proliferate, and at the end of experi-
ment, the cells were lysed by adding the lysis reagent sup-
plied with the kit. Total released LDH was measured with 
the reaction mix from the kit, according to the manufac-
turer’s protocol (Cytotoxicity Detection Kit PLUS (LDH) 
Roch).
Statistical analysis
Statistical analysis was carried out by one-way ANOVA.
In all other cases, the results from at least three indi-
vidual experiments (n ≥  3) were averaged to determine 
mean and statistically significant difference.
Results
In combination with standard chemotherapy, treatment 
with siRNA can also decrease the chemo resistance of 
specific cancers, indicating the potential of siRNA therapy 
for treating many malignant diseases [25]. Two strategies 
must be carefully considered to address safety concerns 
and to guarantee effective, successful treatment of human 
diseases are design and delivery for RNAi effector mol-
ecule [31]. So screening candidate siRNA for homology 
with available sequence databases can, in principle, pre-
dict and avoid several off-target effects we had predicted 
that our desined siRNA has more than 80 % efficiency.
Delivery is probably the only biggest obstacle to 
the development of RNAi-based therapeutic agents. 
Liposomes are commonly used carriers, delivering the 
siRNA with better transfection efficiency and protect-
ing it from degradation [25] Yano et al. have used such a 
liposome to show that anti-bcl-2 siRNA complexed with 
cationic lipid liposome had a strong antitumor activity 
when executed intravenously in the mouse model of liver 
metastasis [32]. So in our study the cell line was trans-
fected using siRNA Transfection Reagent (Santa Cruz 
Biotechnology, Inc), that is a cationic lipid which its com-
ponents are the size of Nano particle that it cause more 
transfection efficiency.
Control siRNA (FluoresceinConjugate)-A is recom-
mended for measuring transfection efficiency of cati-
onic lipid based transfection reagents in cells, in order to 
determine the most suitable transfection reagent to uti-
lize for RNAi studies.
Down regulation of Bcl‑2 mRNA expression in MCF‑7 
breast cancer cells
Specific down regulation of Bcl-2 by antisense oligos or 
siRNA sensitizes cancer cells to chemotherapy or radia-
tion therapy. Hence to inhibit the expression of Bcl-2, 
we applied siRNA to target directly the Bcl-2 transcript. 
We studied time-dependent down regulation of Bcl-2 
and observed that Bcl-2 siRNA-induced down regulation 
of Bcl-2 mRNA, was started at 24 h after treatment but 
an unknown cause led to increase in gene expression of 
Bcl-2 in 48 h after transfection. Interestingly, most of the 
gene silencing of Bcl-2 was observed in 24 h after trans-
fection of siRNA, and it is unlike the previous studies.
Down regulation of Bcl-2 mRNA level was observed 
after 48 h. Interestingly, after 72 h Bcl-2 gene expression 
level came back to normal level. Nevertheless, down reg-
ulation of Bcl-2 transcription level in 24 h was more than 
other periods.
LDH assay test showed no significant sign of cell death
LDH test indicated higher apoptosis in cell treated with 
siRNA in different times in contrast to controls but the 
results were not approved by statistical analysis (no data 
shown).
Bcl‑2 siRNA decrease apoptosis cell death in MCF‑7 cell line
We next evaluated programmed cell death mechanisms, 
including apoptosis. One of the earliest changes during 
apoptosis is translocation of the membrane phospholipid 
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phosphatidyl serine from the inner leaflet of the mem-
brane to the outer one. Therefore, phosphatidyl serine 
expression at the external membrane was investigated by 
the Annexin V assay [33, 34].
No increase in apoptosis was found in MCF-7 cell 
line treated with Bcl-2 siRNA evaluating by Annexin 
staining at 72  h. A time-dependent decrease in apop-
tosis of MCF-7 cell line was associated with down 
regulation of Bcl-2 mRNA. These findings suggest that 
apoptosis inhibition by down regulation of Bcl-2 might 
not play an important role in cell death, and that cell 
death was probably due autophagy.
Discussion
We aimed here to appropriate blocking of the bcl-2 func-
tion as a potent apoptosis trigger by siRNA silencing. 
Fig. 1 Experiment after a 6-h of treatment with the control siRNA. Uptake of FITC-labelled siRNAs of Bcl-2 in MCF-7 cells, verified by fluorescence 
microscope
Fig. 2 a Normal cell line. b 24 h after transfection. c 48 h after transfection. d 72 h after transfection. Probably unknown agent has affected cell line 
viability in 48 h after transfection
Page 5 of 7Talaiezadeh et al. Cancer Cell Int  (2015) 15:105 
On transcription level we observed a time depended and 
significant decreasing of the bcl-2 mRNA. But this event 
was restricted for 24 h. However, in this sight of view, it 
could be the efficient time for appropriate drug therapy 
against chemotherapy resistant tumor cells. The other 
hallmark of the present study was the improvement of 
the idea that the bcl-2 blocking would not necessarily 
lead to apoptosis, but to autophagy, as will be discussed.
The first silencing of the bcl-2 gene by RNAi in MCF-7 
cells was reported by RT Lima et  al. in 2004. They 
showed that down regulation of bcl-2 leads to increase 
of spontaneous apoptosis but at the same time they used 
new designed siRNA targeting gene expression of the 
xIAP inhibiting caspases inhibitors downstream of Bcl-2 
[28]. In 2005, Buchholz TA found that down regulation 
of the Bcl-2 in the MCF-7 cells by siRNA induces cell 
death 50  % above control. However, apoptosis has been 
counted for just 11  % of cell death. They further sug-
gested autophagy as possible alternative cell death. In 
2008 Akar u and et al. provided the first evidence that tar-
geted silencing of Bcl-2 by siRNA induces autophagic cell 
death in breast cancer cells with overexpression of Bcl-2. 
Their findings support the idea that Bcl-2 plays a crucial 
role in inhibition of breast cancer cells from autophagic 
cell death [35]. Our results indicated that the homemade 
siRNA induces effective Bcl-2 gene silencing in MCF7 
cell after 24 h treatment (Fig. 3). But after 48 h of treat-
ment, expression reduction ceases and rises in contrast 
to 24 h and after 72 h the expression level came back to 
normal range. This finding is in relation to the previously 
reported results by Akar U et  al. using Real-time PCR 
and indicates that our homemade siRNA can success-
fully silence the target gene. Further investigation of the 
Bcl-2 expression by Real-time PCR or AnnexinV in the 
present report yielded similar results and approximately 
confirmed each other.
Bcl-2 protein interacts with Beclin 1 protein which is 
an autophagy factor, and Bcl-2 reduction causes Beclin 
1 to release, which triggers autophagy. Apoptosis and 
autophagy are two separated mechanism. It has been 
reported that autophagy blocks apoptosis in some cases. 
To interpret our results, reduction in apoptosis after 24 h 
of treatment with siRNA is due to autophagy activation, 
and sudden reduction of apoptosis after 48  h in con-
trast to 24 and 72 h is probably because of anti-apoptosis 
characteristics of Bcl-2 gene, which results in apoptosis 
reduction.
Based on the fact that the role of autophagy in cell sur-
vival and cell death is debatable, and it is double-edged 
sword, If we assume autophagy occurence by other 
incidences, Bcl-2 silencing probably activates cell sur-
vival mechanism of autophagy that acts as an adaptive 
response to provide nutrients and energy by breaking 
down cellular building blocks such as mitochondria and 
golgi statue, an active bax is localized at the trans-golgi 
network and is one of the main membranes of apoptosis, 
So it may lead to loss of the internal pathway of apopto-
sis. It is probably one of the reasons for decrease in apop-
tosis in AnexinV test results (Fig. 4).
We tried to illustrate conflicting results that observed 
at 48  h after transfection, but as many intracellular 
molecular mechanisms are still unknown furthermore, 
to clarify the relationship between different types of cell 
death, more study is needed, and must provide additional 
tools for analysis these processes.
Also an unfortunate irony of the revolution in under-
standing cancer as a genetic disease is that a single 
accepted treatment directly targets the products of the 
genes that are most frequently activated in human can-
cers without interfering with other pathways in human 
cancers [36]. Although quite a lot of studies have 
been done on Bcl-2, there are numerous unclarified 
Fig. 3 Down regulation of Bcl-2 mRNA after 24, 48 and 72 h of treatment with Bcl-2 siRNA gene silencing
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interactions partners which regulate its activities and 
connect it to a wide variety of cellular pathways.
Although our study confirmed the previous stud-
ies that Bcl-2 gene silencing doesn’t induce apoptosis 
[35, 36], it remains an ongoing mystery how the cells 
‘decide’ to respond to siRNA by preferentially undergoing 
autophagy, and not apoptosis.
In conclusion, our results indicated the possibility of 
complete down regulation of the Bcl-2 mRNA level by 
novel designed Bcl-2 in the MCF-7 human breast can-
cer cells. But, the question remains whether the cell dead 
is due apoptosis or autophagy or even a combination of 
both pathways. However, studies at the molecular level 
on the interplay between autophagy and apoptosis are 
necessary. To explore the sensitization effects of gene 
silencing, Bcl-2 siRNA should also be combined with 
chemotherapeutic agent.
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